Benjamin Oakes is the co-founder and CEO of Scribe Therapeutics, a genetic medicines company unlocking the potential of CRISPR to transform human health. Previously, Oakes was an Innovative Genomics Institute Entrepreneurial Fellow, received a Ph.D. in molecular and cellular biology from the University of California, Berkeley, and worked in the lab of Nobel laureate and CRISPR co-inventor Jennifer Doudna. Oakes and his Scribe team pioneered CRISPR by Design™, a data-driven design and engineering process, to enable a new era of in vivo CRISPR-based standard of care treatments for patients with highly prevalent diseases.
Previously
History was made this year when the first FDA-approved CRISPR-based gene editing therapy became available to patients, designed to cure sickle cell anemia. That represents gr...